David Alan Tepper

David Alan Tepper

David Alan Tepper is an American billionaire hedge fund manager. Tepper is the founder and president of Appaloosa Management Wikipedia

He is the owner of the Carolina Panthers of the National Football League and Charlotte FC in Major League Soccer. Tepper is the founder and president of Appaloosa Management, a global hedge fund based in Miami Beach, Florida.

09/06/2022

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that five abstracts highlighting STS101 and its differentiated features were selected for presentation at the American Headache Society’s (AHS) 64th Annual Scientific Meeting. The 2022 meeting will be held in a hybrid virtual and in-person format at the Ga***rd Rockies Resort in Denver, Colorado from Thursday, June 9 to Sunday, June 12, 2022. Full abstracts are now available on the AHS website and will be published in the journal Headache®.

Oral Presentation
Title: Long-Term Safety and Tolerability of STS101, A Dry Powder Intranasal Dihydroergotamine Product: Initial Data from The ASCEND Study
Presenter: Stewart J. Tepper, M.D.
The Geisel School of Medicine at Dartmouth University
Date: Saturday, June 11, 2022
Session: Industry Abstract Session (7:30 – 9:30am MT)

Accepted Posters
Title: Subject Impression Data for STS101 From the Ongoing Phase 3 Open-Label ASCEND Study
Location: Aurora Hall 3
Poster: P-144
Author(s): Jessica Ailani, MD;
Department of Neurology, Georgetown University, Washington DC, USA
Shannon Strom, PhD;
Satsuma Pharmaceuticals, Inc.
John Kollins, BSE, MBA;
Satsuma Pharmaceuticals, Inc.
Detlef Albrecht, MD
Satsuma Pharmaceuticals, Inc.

Title: Nasal Safety Data of STS101 From the Ongoing Phase 3 Open-Label ASCEND Study
Location: Aurora Hall 3
Poster: P-131
Author(s): Alan M. Rapoport, MD
David Geffen School of Medicine at UCLA, Los Angeles, CA
Shannon Strom, PhD;
Satsuma Pharmaceuticals, Inc.
Detlef Albrecht, MD
Satsuma Pharmaceuticals, Inc.

Title: STS101 Demonstrates Rapid, Consistent Absorption and Sustained Target Plasma Concentrations of Dihydroergotamine (DHE) With Low Variability
Location: Aurora Hall 3
Poster: P-143
Author(s): Egilius L.H. Spierings, MD, PhD
Boston Headache Institute & MedVadis Research Corporation
Shannon Strom, PhD;
Satsuma Pharmaceuticals, Inc.
Detlef Albrecht, MD
Satsuma Pharmaceuticals, Inc.

Title: Relationship of Dihydroergotamine (DHE) Pharmacokinetic Parameters and Clinical Efficacy and Systemic Side Effects
Location: Aurora Hall 3
Poster: P-193
Author(s): John Kollins, BSE, MBA
Satsuma Pharmaceuticals, Inc.
Shannon Strom, PhD;
Satsuma Pharmaceuticals, Inc.
Detlef Albrecht, MD
Satsuma Pharmaceuticals, Inc.
About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained DHE plasma levels over time with low dose-to-dose variability. STS101 also now incorporates an improved 2nd-generation nasal delivery device designed to provide more consistent nasal dosing, irrespective of user administration technique. DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients. However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring an easy-to-carry and easy-to-use dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina.

22/05/2022

Panthers’ David Tepper, billionaire with N.J. roots, is called another Daniel Snyder

Things are not going well for David Tepper.

Yes, he’s the richest owner in the NFL for the third year in a row.

But all the money in the world can’t buy the Carolina Panthers owner some positive press right now. Consider this report from the Boston Globe:

Panthers owner and New Jersey native David Tepper is not making many friends in Charlotte. The Panthers and the town of Rock Hill, S.C., are pointing fingers at each other over failed plans to bring team headquarters, a retail center, concert venue, and more to the Charlotte suburb. The deal was announced in 2019, shovels went in the ground in 2020, but the Panthers halted construction in March when they accused Rock Hill of reneging on a commitment of $225 million in bonds. This past week, the Charlotte Observer reported the project is “dead.” South Carolina state senator Wes Climer quipped that “David Tepper came to Rock Hill promising us Jerry Jones, and ever since then he’s given us Dan Snyder.”

Being compared to Jones is one thing. But Snyder, who’s perhaps the most toxic owner in the NFL? Yikes.

12/05/2022

Panthers owner David Tepper dumps plans for $800M South Carolina headquarters mid-construction, per report

A franchise quarterback isn't the only thing the Panthers are struggling to secure. A month after halting construction on $800 million state-of-the-art headquarters and training facilities in Rock Hill, South Carolina, team owner David Tepper has pulled the plug on the entire project, according to WCNC Charlotte. Tepper's GT Real Estate Holdings confirmed Tuesday that it would be terminating its agreement with the City of Rock Hill to complete the project after a failure to resolve funding issues.

The proposed new facility, whose construction site had been left dormant, broke ground in 2020, just two years after Tepper took ownership of the Panthers. Designed to house a nearly 700,000-square-foot facility on a 240-acre site, complete with an indoor practice field rivaling the Cowboys' famous Frisco, Texas, headquarters, the project was first delayed due to COVID-19. In March, WCNC reported that Rock Hill failed to secure $225 million in bonds to fund roads, sidewalks and other public infrastructure on the site, prompting Tepper's company to pause construction.

Most recently slated for 2023 completion, the facilities now sit empty and half-finished, despite Panthers.com still advertising Rock Hill as the future home to "not only include a world-class sports complex, but also ... a true destination site for the entire region, offering entertainment, dining, retail, athletics and medical care."

The team remains indefinitely headquartered in Charlotte, North Carolina, with Tepper's company suggesting in a statement to WCNC that further conversations will be had with Rock Hill to determine what lies ahead.

"On February 26, 2021, the City of Rock Hill became delinquent on their obligation to fund the public infrastructure," the statement reads. "Despite our persistent efforts throughout 2021, the City of Rock Hill failed to issue the bonds or provide the funding for the public infrastructure for the project ... It is unfortunate that some recently decided to conduct a misguided, destructive public relations campaign to obscure their failures. We have sent notices to the City to formally terminate the previous agreements. Accordingly, we are prepared to sit down with the City and other interested parties to discuss the significant challenges ahead."

Website